皮膚炎用藥與治療 - klpa.taiwan-pharma.org.tw

1 1 2 (Dermatitis) 3 (Contact dermatitis) (Seborrheicdermatitis) (Atopic dermatitis) (Contact dermatitis)5 (Contact dermatitis) ( ) ( ) 6 ( ) ( ) ( )7 ( ) (Skin Patch Test)8 9 Ex 10 (Seborrheic dermatitis)12 (Seborrheic dermatitis) ( ) (Malassezia)13 3 ~12 ( ) ( 25~60 ) ( ) 4~6 14 15 ( ) (Riboflavin Pyridoxine Niacin Zinc EFA) (Malassezia) ?

2 16 AIDS Interferon Lithium Psoralen17 ( ) (atopic dermatitis) (candidiasis) (tinea infection) (psoriasis) (rosacea) (systemic lupus erythematosus) 19 Malassezia Ketoconazole ( ) ( Nizoral ) Bifonazole ( Mycoson ) Ciclopirox ( Brumixol ) ( )20 ( ) Itraconazole Ketoconazole Fluconazole Terbinafine21 Low-potency Super-high-potency 3 22 (Polytarliquid ) Salicylic acid 23 10~15 2~3 24 Selenium sulfide( ) Selsunblue Zincpyrithione 25 (Atopic dermatitis)27 (Atopic dermatitis, Eczema) ( ) (Hay fever) 28 29 30 Th1/Th2 31 (Skin Patch Test)32 - ( )

3 - 33 Crisaborole 35 Diphenhydramine, Hydroxyzine, Cyproheptadine Fexofenadine, Cetirizine, Loratadine36 cream ointment ~ ~ 2 37 (Calcineurininhihiters, CNIs) T Pimecrolimus( Elidel ), Tacrolimus( Protopic ) 2 2 38 Crisaborole Crisaborole(Eucrisa ) PDE4 2016 FDA ~ ( ) BID 39 (Phototherapy) TID 40 Cyclosporine T (Lymphokine) interleukin 2 T (TCGF) ( ) Dupilumab interleukin (IL)4 receptor antagonist 42 2017-6-21 Seborrheic dermatitis in adolescents and adults - of representative topical corticosteroid preparations (classifiedaccording to the US system)Potencygroup*CorticosteroidVehicl etype/formTradenames (UnitedStates)Availablestrength(s),perce nt (except asnoted)Genericavailable inUnitedStatesSuper-highpotency (group 1)Betamethasonedipropionate,augmentedOin tment, ,emollient baseTemovate aerosol(scalp) (scalp)Temovate, (notavailable inUnited States)

4 Ointment, oilycreamNerisone Forte(UnitedKingdom,others) (roll)Cordran4 potency (group 2)AmcinonideOintmentCyclocort , ,augmentedformulation(AF)Diprolene , 2 2017-6-21 Seborrheic dermatitis in adolescents and adults - ,emollientApexiCon potency (group 3)AmcinonideCreamCyclocort , , (notavailable inUnited States)Cream, oilycream,ointmentNerisone(Canada,United Kingdom,others) ,Aristocort (group 4) 2017-6-21 Seborrheic dermatitis in adolescents and adults - mg per 2second sprayNoLower-midpotency (group 5) , , , , sprayCortizone , potency (group 6) , , , 2017-6-21 Seborrheic dermatitis in adolescents and adults - (scalp)Derma- (body)Derma- , potent (group 7)Hydrocortisone(base, 2%) , , AlaScalp, or (base, <2%)OintmentCortaid,Hytone,Nutracort1 YesCreamCortaid,Hytone,Synacort1 YesLotionAquanil HC,Sarnol-HC,Cortizone 101 YesSprayCortaid1 YesSolutionCortaid,Noble, withpramoxine 1%combinationOintmentPramosone1 or ,Analpram-HC1 or ,Analpram-HC1 or foamEpifoam1 Yes* Listed by potency according to the US classification system: group 1 is the most potent, group 7 is the leastpotent.

5 Other countries use a different classification system with only four or five groups. Vehicle and base ingredient(s) for generic products, in some cases, may not be identical to trade version. Inactive United States trade name for specific product; brand may be available outside United States. 48% refined peanut from: Lexicomp Online. Copyright 1978-2017 Lexicomp, Inc. All Rights Reserved; and Tadicherla S,Ross K, Shenefelt D, Topical corticosteroids in dermatology; Journal of Drugs in Dermatology 2009; 12 62402 Version